CHI3L1 and astrocytoma (excluding glioblastoma): Our group demonstrated that integrating the values of CHI3L1 and OPN protein expression in serum with IDH1 mutational status into one parameter could predict patient 24-month survival with 86.8% accuracy for astrocytoma patients of all grades.